FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology. Presented are versions of an antigen-binding polypeptide specific to LIGHT polypeptide characterised by a variable domain of heavy and light chains, as well as versions of based conjugates for treating a disease or a condition. What is described is a pharmaceutical composition for inhibiting apoptosis induced by human LIGHT based on a therapeutically effective amount of the polypeptide. There are disclosed: a method of treating or a diagnosing the disease or condition on the basis of the composition. There are described versions of the recovered polynucleotide or a cell transformed by the polynucleotide for preparing the antigen-binding polypeptide, as well as a method for producing the antigen-binding polypeptide on the basis of the cell.
EFFECT: using the invention provides the antibodies, which block the human or macaque LIGHT interaction to LIGHT receptors that can find application in treating various diseases related to high T-cell activity.
23 cl, 11 dwg, 8 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SINGLE LINKER ANTIBODIES FabFv AND METHODS FOR PRODUCING THEREOF | 2013 |
|
RU2714159C2 |
| HUMANIZING RABBIT ANTIBODIES USING A UNIVERSAL ANTIBODY FRAMEWORK | 2018 |
|
RU2696202C1 |
| HUMANIZATION OF RABBIT ANTIBODIES USING THE UNIVERSAL ANTIBODY FRAME | 2014 |
|
RU2652907C2 |
| HUMANISATION OF RABBIT ANTIBODIES USING UNIVERSAL ANTIBODY SCAFFOLD | 2009 |
|
RU2567006C2 |
| BINDING POLYPEPTIDES AND USE THEREOF | 2006 |
|
RU2470941C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| STRUCTURES AIMED AT AFP/MHC PEPTIDE COMPLEXES AND TYPES OF THEIR USE | 2016 |
|
RU2754041C2 |
| ANTIBODIES AGAINST SIGLEKA-15 FOR TREATING DISEASE ASSOCIATED WITH LOSS OF BONE MASS | 2010 |
|
RU2596392C2 |
| ANTI-KIT ANTIBODIES AND USES THEREOF | 2013 |
|
RU2681730C2 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
